Clinic
Urgent Care Eleven, LLC
Urgent Care Eleven, LLC was paid $10.52M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoURGENT CARE ELEVEN, LLC
NEW ORLEANS, LA 70117
NEW ORLEANS, LA 70117
33aNPI1457761199assigned 05/03/2014
33bProvider typeUrgent Care Clinic/Center
28Total paid$10.52M
24GClaims416,559
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Louisiana
Rank by total paid#10 of 98
Median peer was paid$694K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,009 | $1.04M | |
| 2019 | 45,636 | $1.50M | |
| 2020 | 49,963 | $1.25M | |
| 2021 | 97,154 | $2.48M | |
| 2022 | 94,398 | $2.32M | |
| 2023 | 56,990 | $1.25M | |
| 2024incomplete | 33,409 | $672K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 42,630 | 34,548 | $2.17M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 15% | 21,263 | 17,038 | $1.54M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 14% | 57,432 | 43,054 | $1.51M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 33,229 | 26,684 | $1.05M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 8.6% | 14,690 | 10,623 | $903K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 7.4% | 17,824 | 14,896 | $783K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.7% | 7,273 | 4,719 | $384K |
| 99205 | Prolong outpt/office vis | 3.4% | 3,757 | 3,182 | $360K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.6% | 15,870 | 5,721 | $277K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.6% | 31,903 | 12,926 | $270K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.8% | 5,199 | 4,646 | $189K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 5,987 | 3,282 | $160K |
49 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 7,451 | $143K |
| 99050 | 1.3% | 18,427 | $134K | |
| 81025 | 1.2% | 29,447 | $124K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,867 | $103K |
| 99051 | <1% | 8,696 | $85K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 461 | $47K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 24,471 | $46K |
| 0240U | <1% | 455 | $42K | |
| 86328 | <1% | 1,787 | $38K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 735 | $31K |
| 87634 | <1% | 801 | $26K | |
| G0136 | Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months | <1% | 3,181 | $19K |
| 81003 | <1% | 15,820 | $18K | |
| 87807 | <1% | 1,150 | $11K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,075 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,927 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 716 | $6K |
| 92551 | <1% | 826 | $6K | |
| 0011A | <1% | 402 | $5K | |
| 0012A | <1% | 249 | $4K | |
| 99173 | <1% | 2,896 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 148 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 130 | $2K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 56 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,744 | $2K |
| 0001A | <1% | 75 | $2K | |
| 90656 | <1% | 183 | $1K | |
| 92587 | <1% | 75 | $1K | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 351 | $780.00 |
| 90674 | <1% | 79 | $680.00 | |
| 82962 | <1% | 358 | $543.24 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 23 | $537.46 |
| Q3014 | Telehealth originating site facility fee | <1% | 233 | $440.00 |
| 90756 | <1% | 36 | $413.32 | |
| 0002A | <1% | 31 | $334.56 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 201 | $317.67 |
| 72040 | <1% | 13 | $256.52 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,048 | $245.27 |
| 72100 | <1% | 12 | $244.90 | |
| 82948 | <1% | 199 | $237.00 | |
| 90714 | <1% | 23 | $213.48 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 87 | $84.72 |
| 91301 | <1% | 321 | $74.16 | |
| 76140 | <1% | 1,630 | $45.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16 | $11.70 |
| 91300 | 0% | 88 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 1,116 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 17 | $0.00 |
| 99000 | 0% | 369 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROUSSELL, CINDY (MANAGER)